Investigating how a blood protein system affects Alzheimer's disease and potential treatments.
Contact System and Alzheimer's Disease: Mechanism and Therapeutic Potential
['FUNDING_R01'] · ROCKEFELLER UNIVERSITY · NIH-10802820
This study is looking at how a part of your blood called the plasma contact system affects Alzheimer's disease and how it interacts with a protein that plays a big role in the disease, while also testing if a new treatment can work better when combined with another medication.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROCKEFELLER UNIVERSITY (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10802820 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the plasma contact system in Alzheimer's disease (AD), particularly how it interacts with the beta-amyloid peptide, a key factor in the disease's progression. The study aims to explore the mechanisms by which this system contributes to neurodegeneration and cognitive decline in AD patients. Researchers will investigate the effects of the FDA-approved antibody therapy lecanemab on this system and whether combining it with a contact system inhibitor could enhance treatment outcomes. By studying these interactions, the research seeks to uncover new therapeutic strategies for managing Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those who may benefit from new therapeutic approaches.
Not a fit: Patients with other forms of dementia or cognitive decline unrelated to Alzheimer's disease may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for Alzheimer's disease, potentially slowing its progression and enhancing cognitive function.
How similar studies have performed: Previous research has shown promising results in targeting the beta-amyloid peptide and its interactions, indicating potential for success with this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- ROCKEFELLER UNIVERSITY — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STRICKLAND, SIDNEY — ROCKEFELLER UNIVERSITY
- Study coordinator: STRICKLAND, SIDNEY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease model, Alzheimer's disease pathology